Opus Genetics, Inc. (IRD)
NASDAQ: IRD · Real-Time Price · USD
4.160
+0.570 (15.88%)
At close: Feb 27, 2026, 4:00 PM EST
4.140
-0.020 (-0.48%)
After-hours: Feb 27, 2026, 7:57 PM EST
Opus Genetics Revenue
Opus Genetics had revenue of $3.08M in the quarter ending September 30, 2025, a decrease of -20.38%. This brings the company's revenue in the last twelve months to $14.63M, up 74.60% year-over-year. In the year 2024, Opus Genetics had annual revenue of $10.99M, down -42.30%.
Revenue (ttm)
$14.63M
Revenue Growth
+74.60%
P/S Ratio
19.61
Revenue / Employee
$812,944
Employees
18
Market Cap
286.89M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 10.99M | -8.06M | -42.30% |
| Dec 31, 2023 | 19.05M | -20.80M | -52.20% |
| Dec 31, 2022 | 39.85M | 39.26M | 6,665.70% |
| Dec 31, 2021 | 589.00K | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | 75.00K | - | - |
| Dec 31, 2007 | 75.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Puma Biotechnology | 228.37M |
| Cellectis | 82.55M |
| Fennec Pharmaceuticals | 38.79M |
| X4 Pharmaceuticals | 33.98M |
| AC Immune | 5.48M |
| Abeona Therapeutics | 400.00K |
| Inhibikase Therapeutics | 1.00 |
| Adlai Nortye | -1.35M |
IRD News
- 17 hours ago - Opus Genetics Announces Initial Clinical Data from Phase 1/2 OPGx-BEST1 Gene Therapy Study at the Macula Society Annual Meeting - GlobeNewsWire
- 2 days ago - Opus Genetics Announces FDA Acceptance of Supplemental New Drug Application for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia - GlobeNewsWire
- 5 days ago - Opus Genetics: Asymmetric Upside With LCA5 And BEST1 - Seeking Alpha
- 14 days ago - Opus Genetics Announces $25 Million Private Placement - GlobeNewsWire
- 25 days ago - Opus Genetics to Participate in Upcoming Medical and Industry Conferences in February 2026 - GlobeNewsWire
- 4 weeks ago - Opus Genetics Launches Gene Therapy Clinical Trial for MERTK-related Retinitis Pigmentosa - GlobeNewsWire
- 6 weeks ago - Opus Genetics, Inc. (IRD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 7 weeks ago - Opus Genetics Highlights 2025 Progress and Upcoming 2026 Catalysts - GlobeNewsWire